Israeli biotech firm Innocan Pharma has unveiled a groundbreaking CBD injection that holds significant promise in the global veterinary field. This advanced Liposomal CBD (LPT-CBD) treatment was successfully tested on an elderly donkey, Ariel, delivering notable results that could pave the way for human applications in the future.
Ariel, a 35-year-old donkey residing at a rescue farm in Israel, developed osteoarthritis after years of bearing excessive loads. In a compassionate bid to ease her suffering, researchers administered a single injection of LPT-CBD, which targets chronic pain through a sustained-release formulation.
Revolutionizing Veterinary Care: The Role of CBD Shots
The veterinary world is witnessing a shift with the introduction of Liposomal CBD (LPT-CBD)—a powerful pain management solution. Here’s why it’s making headlines:
- Single-Shot Relief: One injection provided Ariel with weeks of improved mobility.
- Long-Lasting Impact: A second shot led to sustained relief, proving the treatment’s effectiveness.
- Future Human Applications: Following successful pre-IND meetings with the FDA, LPT-CBD shows promise as a non-opioid alternative for chronic pain in humans.
Did You Know? LPT-CBD’s unique liposomal formulation ensures sustained CBD release, offering prolonged pain relief.
Meet Ariel: The Donkey Leading CBD Research
Living at a rescue farm in Israel, Ariel became an unlikely pioneer in cannabis research. Suffering from severe osteoarthritis, she became the first large animal treated with Innocan’s LPT-CBD. According to the company, her mobility improved remarkably, prompting further studies into the potential of this innovative treatment.
Why LPT-CBD is a Game-Changer in Pain Management
- Proven Effectiveness: Ariel’s rapid recovery showcases the product’s potential for large animals like pigs and ruminants.
- Non-Opioid Alternative: LPT-CBD’s prolonged pain relief opens new possibilities for chronic pain treatment without relying on opioids.
- Broad Veterinary Applications: Beyond donkeys, the treatment could benefit various animals, revolutionizing how veterinarians manage pain.
Expert Insights: Why This Matters
Prof. Chezy Barenholz, head of Innocan’s Scientific Advisory Board, emphasizes the breakthrough:
“Ariel’s quick and prolonged relief, paired with previous studies, proves that LPT-CBD can transform veterinary pain management.”
Dr. Eyal Kalo, Innocan’s R&D director, adds:
“The positive outcomes seen in Ariel add to growing evidence that LPT-CBD may become a powerful, non-opioid solution for human pain management.”
Understanding LPT-CBD: What Makes It Unique?
LPT-CBD isn’t just any CBD treatment. It’s a patented liposomal formulation designed for:
- Sustained CBD Release: Ensuring prolonged relief with fewer injections.
- Targeted Pain Management: Effective for chronic pain in both animals and humans.
- Versatile Applications: Potential uses span across the veterinary field and human medicine.
The Future of Pain Treatment: From Animals to Humans
Ariel’s successful treatment marks just the beginning. With LPT-CBD passing crucial pre-IND meetings with the FDA, there’s a strong possibility it could soon become a staple in human pain management. The story of one donkey’s relief may pave the way for millions dealing with chronic pain.
Final Thoughts:
Innocan Pharma’s LPT-CBD treatment not only gave Ariel a second chance at a comfortable life but also signaled a revolutionary shift in pain management. With promising applications for both animals and humans, the future of compassionate, non-opioid pain relief looks brighter than ever.